Evaluation and Determination of Quantitative Hepatitis B Surface Antigen Diagnostic Performance in Chronic Hepatitis B Virus-Infected Patients

Background Hepatitis B virus DNA (HBV-DNA) assessment is recommended for diagnosing and monitoring chronic hepatitis (CHB) patients. Quantitative surface antigen (qHBsAg) estimation adjunct to HBV-DNA vital assessing HBV chronicity therapeutic prognosis. This study aimed estimate the qHBsAg compare its diagnostic performance with that of levels in CHB patients from Bangladesh. Methodology A total 148 were enrolled this study. e-antigen (HBeAg) estimated using chemiluminescent enzyme immunoassays, respectively, was quantified real-time polymerase chain reaction. The parameters performances analyzed by receiver operating characteristic (ROC) curve analysis. Results overall (mean ± SD) qHBsAg, HBV-DNA, alanine aminotransferase (ALT) among population (n = 148) 3.45 0.80 log10 IU/mL, 4.40 2.44 86.17 39.06 IU/L, respectively. Significant differences observed both (p 0.004) < 0.0001) cases HBeAg positivity. showed a weak positive correlation ALT HBeAg-positive patients, but no such relationship HBeAg-negative ROC analysis area under level distinguish high (>5 IU/mL) 0.653 0.002), which indicated an acceptable performance. best cut-off predicting 3.469 IU/mL. Conclusions Our results might be useful marker throughout treatment follow-up.